Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ligand Pharm (LGND)

Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,876,680
  • Shares Outstanding, K 18,000
  • Annual Sales, $ 131,310 K
  • Annual Income, $ 52,150 K
  • 60-Month Beta 1.01
  • Price/Sales 14.61
  • Price/Cash Flow 20.94
  • Price/Book 2.43
Trade LGND with:

Options Overview Details

View History
  • Implied Volatility 42.72% ( -0.75%)
  • Historical Volatility 33.65%
  • IV Percentile 74%
  • IV Rank 58.15%
  • IV High 53.63% on 08/05/24
  • IV Low 27.55% on 09/19/23
  • Put/Call Vol Ratio 0.33
  • Today's Volume 4
  • Volume Avg (30-Day) 16
  • Put/Call OI Ratio 0.17
  • Today's Open Interest 986
  • Open Int (30-Day) 926

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 0.90
  • Number of Estimates 1
  • High Estimate 0.90
  • Low Estimate 0.90
  • Prior Year 0.71
  • Growth Rate Est. (year over year) +26.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
98.89 +6.18%
on 09/04/24
108.83 -3.52%
on 08/29/24
+2.79 (+2.73%)
since 08/16/24
3-Month
77.53 +35.43%
on 06/26/24
112.13 -6.35%
on 07/31/24
+24.46 (+30.37%)
since 06/18/24
52-Week
49.24 +113.24%
on 10/27/23
112.13 -6.35%
on 07/31/24
+42.44 (+67.84%)
since 09/18/23

Most Recent Stories

More News
3 'Strong Buy' Small-Cap Stocks to Snag Now for a Soft Landing

Explore three small-cap stocks with 'Strong Buy' ratings that are poised for significant growth as economic conditions hint at a potential soft landing.

KNSA : 25.40 (+0.04%)
LGND : 103.84 (-0.40%)
SCI : 79.67 (-1.10%)
VBR : 198.57 (+0.26%)
VKTX : 64.87 (+3.07%)
Ligand: Q2 Earnings Snapshot

Ligand: Q2 Earnings Snapshot

LGND : 103.84 (-0.40%)
3 Magnificent Growth Stocks to Buy Hand Over Fist

Small-cap stocks could get a boost from the central bank's anticipated rate cuts in 2025. These three stocks may be a great way to get ahead of this catalyst.

LGND : 103.84 (-0.40%)
AGEN : 6.16 (-1.12%)
CGC : 4.80 (-1.84%)
CURLF : 3.0535 (+3.16%)
Ligand: Q1 Earnings Snapshot

Ligand: Q1 Earnings Snapshot

LGND : 103.84 (-0.40%)
Ligand: Q4 Earnings Snapshot

Ligand: Q4 Earnings Snapshot

LGND : 103.84 (-0.40%)
Ligand: Q3 Earnings Snapshot

Ligand: Q3 Earnings Snapshot

LGND : 103.84 (-0.40%)
Ligand: Q2 Earnings Snapshot

Ligand: Q2 Earnings Snapshot

LGND : 103.84 (-0.40%)
Ligand: Q1 Earnings Snapshot

Ligand: Q1 Earnings Snapshot

LGND : 103.84 (-0.40%)
Ligand Reports First Quarter 2023 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three months ended March 31, 2023, and provided an operating forecast and business updates. Ligand management...

LGND : 103.84 (-0.40%)
TVTX : 14.24 (-1.11%)
VKTX : 64.87 (+3.07%)
NOVN : 0.0941 (-24.84%)
NVS : 115.93 (+0.20%)
ANEB : 2.23 (-1.76%)
Ligand to Report First Quarter 2023 Financial Results on May 4, 2023

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report first quarter 2023 financial results after the close of the U.S. financial markets on Thursday, May 4, 2023, and will hold a conference call...

LGND : 103.84 (-0.40%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ligand, being a biotechnology company, focuses on developing/acquiring royalty revenue generating assets and coupling them with a lean corporate cost structure. Ligand's Captisol formulation technology has allowed it to enter into several licensing deals and generate royalties. Captisol is a well validated...

See More

Key Turning Points

3rd Resistance Point 108.02
2nd Resistance Point 107.17
1st Resistance Point 105.72
Last Price 103.84
1st Support Level 103.41
2nd Support Level 102.56
3rd Support Level 101.10

See More

52-Week High 112.13
Last Price 103.84
Fibonacci 61.8% 88.10
Fibonacci 50% 80.68
Fibonacci 38.2% 73.26
52-Week Low 49.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar